Arkema Acquires Majority Stake in Proionic for Next-Gen Batteries

Arkema is set to acquire a 78% stake in Proionic, a start-up specializing in ionic liquids production. These components are crucial for future lithium-ion batteries. This acquisition expands Arkema’s solutions and strengthens its position in the materials sector across various battery technologies.

Proionic, a leading start-up in ionic liquids, was founded by Roland Kalb in 2004 in Graz, Austria. The company’s innovative technologies allow for the synthesis and recycling of these liquids, which are essential for next-gen solid and flexible batteries due to their electrical conductivity and non-flammability.

Armand Ajdari, Arkema's Chief Technology Officer commented, "With Proionic, Arkema continues to enrich its unique portfolio of differentiating technologies, and strengthens its position as the partner of choice for co-developing the safer, more efficient and more sustainable batteries of the future. We are delighted to welcome Proionic's teams to this great adventure."

Arkema’s acquisition of Proionic strengthens its position in the battery ecosystem and expands its high-performance materials portfolio. Ionic liquids, key to Proionic’s success, are used in biomass processing and metal treatment, aligning with Arkema’s sustainable solutions strategy. With €2.5 million sales in 2023, Proionic is expected to grow rapidly due to synergies with Arkema.

 

Company

Logo:

Arkema

420 rue d’Estienne d’Orves
92705 Colombes Cedex
France

Company contact







Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.